Transcranial photobiomodulation increases cognition and serum BDNF levels in adults over 50 years: A randomized, double-blind, placebo-controlled trial.

Bruna H de Oliveira, Elisa F Lins, Naiara F Kunde, Afonso S I Salgado, Leidiane M Martins, Franciane Bobinski, Willians F Vieira, Paolo Cassano, Anna Quialheiro, Daniel F Martins

Experimental Neuroscience Laboratory (LaNEx), University of South Santa Catarina, Palhoça, Santa Catarina, Brazil; Postgraduate Program in Health Sciences, University of South Santa Catarina, Palhoça, Santa Catarina, Brazil.Experimental Neuroscience Laboratory (LaNEx), University of South Santa Catarina, Palhoça, Santa Catarina, Brazil; Postgraduate Program in Health Sciences, University of South Santa Catarina, Palhoça, Santa Catarina, Brazil. · pubmed

Paper

Abstract

There is a significant lack of therapeutic options for mild cognitive impairment (MCI), which is rapidly becoming a global epidemic due to aging. Transcranial photobiomodulation (t-PBM) involves delivering near-infrared light (NIR) to the scalp, targeting cortical areas of the brain. NIR t-PBM has recently emerged as a potential therapy for various neurodegenerative conditions, including memory issues.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper addresses a therapeutic approach (transcranial photobiomodulation) that targets cognitive decline, which is a significant concern in the context of aging and age-related diseases. While it presents solid research findings, the impact is limited as it primarily focuses on a treatment for symptoms of mild cognitive impairment rather than addressing the underlying mechanisms of aging itself. Thus, while it contributes to the field, it does not represent a major breakthrough or transformative work.

Author of this paper? Send a correction.